scholarly journals Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada

2021 ◽  
Vol 13 ◽  
pp. 175883592199298
Author(s):  
Maryam Darvishian ◽  
Zahid A. Butt ◽  
Stanley Wong ◽  
Eric M. Yoshida ◽  
Jaskaran Khinda ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Population Based ◽  
Infection Status ◽  
Pancreatic Cancers ◽  
Cancer Occurrence ◽  
Liver Cancers ◽  
B Virus ◽  
Proportional Subdistribution Hazards ◽  
Risk Of Cancer ◽  
The Impact

Introduction:Studies of the impact of hepatitis C virus (HCV), hepatitis B virus (HBV) and HIV mono and co-infections on the risk of cancer, particularly extra-hepatic cancer, have been limited and inconsistent in their findings.Methods:In the British Columbia Hepatitis Testers Cohort, we assessed the risk of colorectal, liver, and pancreatic cancers in association with HCV, HBV and HIV infection status. Using Fine and Gray adjusted proportional subdistribution hazards models, we assessed the impact of infection status on each cancer, accounting for competing mortality risk. Cancer occurrence was ascertained from the BC Cancer Registry.Results:Among 658,697 individuals tested for the occurrence of all three infections, 1407 colorectal, 1294 liver, and 489 pancreatic cancers were identified. Compared to uninfected individuals, the risk of colorectal cancer was significantly elevated among those with HCV (Hazard ration [HR] 2.99; 95% confidence interval [CI] 2.55–3.51), HBV (HR 2.47; 95% CI 1.85–3.28), and HIV mono-infection (HR 2.30; 95% CI 1.47–3.59), and HCV/HIV co-infection. The risk of liver cancer was significantly elevated among HCV and HBV mono-infected and all co-infected individuals. The risk of pancreatic cancer was significantly elevated among individuals with HCV (HR 2.79; 95% CI 2.01–3.70) and HIV mono-infection (HR 2.82; 95% CI 1.39–5.71), and HCV/HBV co-infection.Discussion/Conclusion:Compared to uninfected individuals, the risk of colorectal, pancreatic and liver cancers was elevated among those with HCV, HBV and/or HIV infection. These findings highlight the need for targeted cancer prevention and diligent clinical monitoring for hepatic and extrahepatic cancers in infected populations.

scholarly journals Identification of domestic cat hepadnavirus from a cat blood sample in Japan

2022 ◽  
Author(s):  
Kazuki Takahashi ◽  
Yasuyuki Kaneko ◽  
Akiko Shibanai ◽  
Shushi Yamamoto ◽  
Ayana Katagiri ◽  
...  
Keyword(s):  
Phylogenetic Analysis ◽  
Chronic Hepatitis ◽  
Blood Sample ◽  
Domestic Cat ◽  
Hepatic Cancer ◽  
Infection Status ◽  
Domestic Cats ◽  
Hepatic Diseases ◽  
B Virus ◽  
The Impact

The hepatitis B virus (Hepadnaviridae) induces chronic hepatitis and hepatic cancer in humans. A novel domestic cat hepadnavirus (DCH) was recently identified in several countries, however, the DCH infection status of cats in Japan is unknown. Therefore, we investigated the DCH infection rate of 139 cat samples collected in Japan. We identified one positive blood sample (0.78%) from a 17-year-old female cat with chronically elevated alanine aminotransferase. Phylogenetic analysis demonstrated that the DCH strain identified in this study is genetically distinct from strains in other countries. Further investigations are required to elucidate the evolution of DCH and the impact of DCH infection on hepatic diseases in domestic cats.

scholarly journals Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Busayo I. Ajuwon ◽  
Isabelle Yujuico ◽  
Katrina Roper ◽  
Alice Richardson ◽  
Meru Sheel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Disease Surveillance ◽  
Control Strategies ◽  
Meta Analysis ◽  
Population Based ◽  
North West ◽  
B Virus ◽  
The Impact

Abstract Background Hepatitis B virus (HBV) is an infectious disease of global significance, causing a significant health burden in Africa due to complications associated with infection, such as cirrhosis and liver cancer. In Nigeria, which is considered a high prevalence country, estimates of HBV cases are inconsistent, and therefore additional clarity is required to manage HBV-associated public health challenges. Methods A systematic review of the literature (via PubMed, Advanced Google Scholar, African Index Medicus) was conducted to retrieve primary studies published between 1 January 2010 and 31 December 2019, with a random-effects model based on proportions used to estimate the population-based prevalence of HBV in the Nigerian population. Results The final analyses included 47 studies with 21,702 participants that revealed a pooled prevalence of 9.5%. A prevalence estimate above 8% in a population is classified as high. Sub-group analyses revealed the highest HBV prevalence in rural settings (10.7%). The North West region had the highest prevalence (12.1%) among Nigeria’s six geopolitical zones/regions. The estimate of total variation between studies indicated substantial heterogeneity. These variations could be explained by setting and geographical region. The statistical test for Egger’s regression showed no evidence of publication bias (p = 0.879). Conclusions We present an up-to-date review on the prevalence of HBV in Nigeria, which will provide critical data to optimise and assess the impact of current prevention and control strategies, including disease surveillance and diagnoses, vaccination policies and management for those infected.

Body Image and the Cancer Treatment Trajectory

2018 ◽  
Author(s):  
Kerry A. Sherman ◽  
Laura-Kate E. Shaw
Keyword(s):  
Body Image ◽  
Cancer Treatment ◽  
Cancer Detection ◽  
Well Being ◽  
Prophylactic Surgery ◽  
Premature Menopause ◽  
Cancer Occurrence ◽  
Body Image Concerns ◽  
Risk Of Cancer ◽  
The Impact

Abstract: The chapter “Body Image and the Cancer Treatment Trajectory” provides an overview of body image–related concerns and challenges that can arise throughout the cancer journey, from cancer detection and diagnosis through to active treatment and cancer survivorship. The chapter examines how body image concerns can serve as a significant barrier to cancer detection, including self- and physician examination, routine screening, and diagnostic tests. It then reviews the impact of cancer surgery and treatment-related side effects (such as physical disfigurement, hair loss, skin irritations, weight loss or gain, changes to bodily functions, premature menopause, and lymphedema) on an individual’s body image, self-concept, and overall psychosocial well-being in both the short and longer term. Finally, the chapter discusses body image concerns arising from risk-reducing or prophylactic surgery to minimize hereditary risk of cancer occurrence.

Cancer risk of aged people with HIV infection and of transplant people

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20063-20063
Author(s):  
D. Serraino ◽  
P. Piselli ◽  
G. Busnach ◽  
F. Citterio ◽  
L. Fratino ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Hiv Infection ◽  
Older Individuals ◽  
Aged People ◽  
Highly Active ◽  
Increased Risk ◽  
The Difference ◽  
Few Data ◽  
Risk Of Cancer ◽  
The Impact

20063 Background: Acquired immunesuppression due to HIV-infection or to anti-rejection therapies following organ transplantation is a well known risk factor for cancer. This increased risk has been well documented for young adults, whereas few data are available on older persons. In this study, we assessed the impact of cancer in HIV-positive persons (HIV+) and in transplant persons (TRP) who were 50 years of age or older. Methods: Data from a multi-cohort study conducted in Italy and France were analysed. Individuals ≥50 years of age were selected from the original study group constituted by 2002 HIV+ seroconverters from Italy, 6072 HIV+ from France and 2755 Italian TRP (1844 kidney, 702 heart, 159 liver and 50 lung TRP). Sex- and age-standardized incidence ratios (SIR) and 95% confidence intervals (CI) were computed to quantify the cancer risk as compared to the general population. Among HIV+, the risk of cancer was also assessed according to treatment with highly active antiretroviral therapies (HAART). Results: This analysis was based on 94 cancers diagnosed in 833 HIV+, and on 154 cancers diagnosed in 1558 TRP ≥50 years of age. The SIRs for all cancers decreased with ageing, ranging from 5.1 (95% CI: 4.0–6.5) in HIV+ aged 50–59 to 2.1 (95% CI: 1.4–3.1) in HIV+ aged 60 or older. In TRP, the SIRs for all cancer were 2.5 (95% CI:2.0–3.1) and 1.6 (95% CI: 1.2–2.0), respectively. In HIV+, the protective effect of HAART was more evident in those aged 50–59 (SIR = 6.8 in never treated and SIR = 2.4 in ever treated) than in HIV+ aged ≥60 (SIR = 2.8 and SIR = 1.6, respectively). This pattern of cancer occurrence was peculiar to virus-related cancers (e.g., Kaposi’s sarcoma, non-Hodgkin’s lymphoma, liver cancer). SIRs for lung cancer in both groups were significantly increased but did not significantly differ according to HAART and/or age. The survival of both HIV+ and TRP was significantly reduced by the diagnosis of cancer, but the difference in survival was not associated with ageing (p = 0.20). Conclusions: Aged individuals with acquired immunesuppression have a cancer pattern similar to younger persons with immunosuppression, but the burden of cancer will increase in absolute terms because of the increasing proportion of older individuals among both HIV+ and TRP. No significant financial relationships to disclose.

Abstract P167: Title: Prediction of Arterial Stiffness from Early T-cell Activation among HIV and HCV Co-infected Women in the Women's Interagency HIV Study (WIHS)

Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Roksana Karim ◽  
Naoko Kono ◽  
Robert Kaplan ◽  
Wendy J Mack ◽  
Howard N Hodis ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Arterial Stiffness ◽  
Hiv Infection ◽  
T Cell Activation ◽  
Cell Activation ◽  
Infection Status ◽  
Activation Markers ◽  
Color Flow ◽  
The Impact

Introduction: Activation of T-lymphocytes, a hallmark of HIV infection, reaches a set point early in HIV infection and persists even after viral suppression with highly active antiretroviral therapy (HAART). Early T-cell activation predicts subsequent CD4 depletion, progression to AIDS and survival. HIV-infected subjects are at high risk for premature atherosclerosis. Little is known regarding the impact of early T cell activation on arterial stiffness. While Kaplan et al. (2011) were the first and only group to show a cross-sectional association, we investigate here if early T cell activation can predict future arterial stiffness. Hypothesis: High early T cell activation will predict increased arterial stiffness, measured 5.5 (IQR=2.5-7.5) years later, in HIV and HCV co-infected women. Methods: A longitudinal study nested within the WIHS, an ongoing prospective cohort study. Percentages of CD4 and CD8 T cell activation, assessed by CD38 and HLA-DR co-expression using 3-color flow cytometry, were measured on average 5.5 years before arterial stiffness assessments (carotid artery distensibility, and Young’s elastic modulus for elasticity) using B-mode carotid ultrasound. Multiple linear regression models evaluated the association between log-transformed T cell activation markers (independent variables) and arterial stiffness (dependent variable). Analyses were stratified by HCV co-infection status and by pre- and post-HAART assessment of T cell activation. Results: A total of 376 HIV+ women (185 HCV+) were included in the analysis. Participants were on average 46(SD=9) years old, 59% Black, and 49% were current smokers. Activation of both CD4 and CD8 T cells significantly univariately predicted reduced distensibility and elasticity among HIV-infected women. CD4 activation continued to significantly predict distensibility (β(SEM)= −3.51(1.30) 10 −6* N −1* m 2 , p=0.01), and elasticity (0.11(0.04)10 5* N * m 2 , p=0.004) with adjustment for age, race, BMI, smoking, ART, CD4 count, and HIV RNA. CD8 activation was no longer associated after adjustment. When stratified by HCV co-infection status, the prediction of arterial stiffness parameters from early CD4 activation was somewhat stronger among the HIV+/HCV+ women compared to HIV+/HCV- women (β(SEM)= −4.44(1.93), p=0.02 vs. −3.04(1.84), p=0.10 for distensibility, and 0.17(0.06), p=0.003 vs. 0.09(0.05), p=0.09 for elasticity); however the test for interaction was not statistically significant. In a subset of 188 women, CD4 activation measured both pre- and post-HAART significantly predicted later arterial stiffness. Conclusions: CD4 activation level predicts future arterial stiffness in HIV-infected women, perhaps more markedly among HCV co-infected women. These data confirm the proinflammatory impact of activated T cells that can cause vascular dysfunction and shed light on the early onset of atherogenesis.

Microscopic Colitis and Risk Of Cancer—AA Population-Based Cohort Study

2020 ◽  
Author(s):  
David Bergman ◽  
Hamed Khalili ◽  
Bjorn Roelstraete ◽  
Jonas F Ludvigsson
Keyword(s):  
Cohort Study ◽  
Reference Group ◽  
Large Population ◽  
Population Based ◽  
Microscopic Colitis ◽  
First Year ◽  
Increased Risk ◽  
Risk Of Cancer ◽  
The Impact

Abstract Background and Aims The association between microscopic colitis [MC] and cancer risk is unclear. Large, population-based studies are lacking. Methods We conducted a nationwide cohort study of 11 758 patients with incident MC [diagnosed 1990–2016 in Sweden], 50 828 matched reference individuals, and 11 614 siblings to MC patients. Data were obtained through Sweden´s pathology departments and from the Swedish Cancer Register. Adjusted hazard ratios [aHRs] were calculated using Cox proportional hazards models. Results At the end of follow-up [mean: 6.7 years], 1239 [10.5%] of MC patients had received a cancer diagnosis, compared with 4815 [9.5%] of reference individuals (aHR 1.08 [95% confidence interval1.02–1.16]). The risk of cancer was highest during the first year of follow up. The absolute excess risks for cancer at 5, 10, and 20 years after MC diagnosis were + 1.0% (95% confidence interval [CI] 0.4%-1.6%), +1.5% [0.4%-2.6%], and + 3.7% [-2.3–9.6%], respectively, equivalent to one extra cancer event in every 55 individuals with MC followed for 10 years. MC was associated with an increased risk of lymphoma (aHR 1.43 [1.06–1.92]) and lung cancer (aHR 1.32 [1.04–1.68]) but with decreased risks of colorectal (aHR 0.52 [0.40–0.66]) and gastrointestinal cancers (aHR 0.72 [0.60–0.85]). We found no association with breast or bladder cancer. Using siblings as reference group to minimise the impact of shared genetic and early environmental factors, patients with MC were still at an increased risk of cancer (HR 1.20 [1.06–1.36]). Conclusions This nationwide cohort study demonstrated an 8% increased risk of cancer in MC patients. The risk was highest during the first year of follow-up.

scholarly journals Impact of Sleeping Duration on the Risk of Breast Cancer: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Amos Ochieng Okutse
Keyword(s):  
Breast Cancer ◽  
Cohort Studies ◽  
Meta Analysis ◽  
Population Based ◽  
Women Studies ◽  
Long Sleep ◽  
Study Heterogeneity ◽  
Funnel Plots ◽  
Risk Of Cancer ◽  
The Impact

Background: The impact of different sleeping categories on the risk of cancer of the breast has remained debatable. We sought to systematically synthesize the fund of available literature on this relationship from population-based cohort studies using meta-analytic procedures. Data sources: Studies about napping and cancer of the breasts were identified from databases up to February 2019. Methods: Identified studies were analyzed for quality using NOS Scores. Effect sizes were visualized using funnel plots. Study heterogeneity was quantified using I2 and visualized using Baujat plots. Publication prejudice was evaluated using Eggers regression model, with visualizations using funnel plots. Analysis were done using R. Results: Eight cohort studies met the inclusion criteria. Random effects model revealed non-statistically significant evidence of an association between short or long sleep and breast cancer OR=0.90;(95%CI 0.7995-1.0215); p=0.1054 and OR=0.95(0.8886-1.0280);p=0.2234 respectively. There was moderate to high heterogeneity I2(95%CI)=74.4%(48.2%-87.4%) among studies examining short sleep and cancer of the breast, and low to moderate heterogeneity in studies for long sleep and breast cancer I2(95%CI)=3.0%(0.0%-68.6%). Conclusions: This study found non substantial evidence of associations between sleeping periods and cancer of the breast in women. Studies employing novel sleep measurement methodologies should be carried out to examine the underlying relationship.

Sign in / Sign up

Export Citation Format

Share Document